Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

Tirzepatide and GLP-1 receptor agonists are replacing older treatments, marking a shift in how diabetes and weight loss are ...

You may know about tirzepatide, also known as Mounjaro or Zepbound, due to its popularity for those looking to lose weight or treat diabetes. Now, researchers have gotten it approved to treat sleep ...

Tirzepatide was approved in November 2023 by the US Food and Drug Administration (FDA) (Zepbound) and in the EU in June 2024 (Mounjaro) for weight management in adults with obesity or overweight ...

They're offered in several brand name forms, like Ozempic, where semaglutide is the main substance, or Zepbound, where tirzepatide is the main substance. But they do basically the same thing.

Zepbound belongs to a class of drugs called dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist. It contains the active ingredient tirzepatide and comes ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in with the new.

The risk of both all-cause deaths and those caused by cardiovascular conditions in OSA patients is significantly reduced with the use of CPAP therapy.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...